You are here

  • Home
  • Archive
  • Volume 5, Issue 1
  • Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)

Article metrics

Article menu

Download PDFPDF

XML
Inflammatory bowel disease
Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)

 

Online download statistics by month:

Online download statistics by month: July 2018 to March 2024

AbstractFullPdf
Jul 2018566558111
Aug 2018552543104
Sep 201823423453
Oct 201813513440
Nov 201819719736
Dec 201823323325
Jan 201919919936
Feb 201919318930
Mar 201914113822
Apr 201913613120
May 201911310721
Jun 2019636216
Jul 2019575020
Aug 201910910624
Sep 201928274
Oct 2019403911
Nov 2019403414
Dec 201929288
Jan 2020282713
Feb 2020363510
Mar 2020444120
Apr 202031307
May 2020282811
Jun 2020363719
Jul 202028286
Aug 202015156
Sep 202040399
Oct 202055557
Nov 202049478
Dec 2020444112
Jan 2021474316
Feb 2021515021
Mar 2021504827
Apr 202139348
May 202144425
Jun 202135345
Jul 2021363513
Aug 2021252518
Sep 2021282811
Oct 2021333225
Nov 2021444421
Dec 2021393914
Jan 202224268
Feb 202237398
Mar 2022363618
Apr 2022394118
May 2022353215
Jun 2022343412
Jul 202237317
Aug 2022373415
Sep 2022252824
Oct 2022313010
Nov 2022484618
Dec 2022383822
Jan 2023383821
Feb 202337374
Mar 2023292912
Apr 2023303114
May 2023747318
Jun 202330309
Jul 202317178
Aug 202321189
Sep 202323195
Oct 2023333114
Nov 202334337
Dec 2023373215
Jan 202425214
Feb 2024372414
Mar 2024323112
Total488847651248